Latest News

Vaginal estrogen not recommended with aromatase inhibitors

Publish date: October 24, 2022

 

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Switching to fulvestrant + palbociclib benefits ER + HER2− BC patients with rising bESR1mut
MDedge Hematology and Oncology
Metastatic TNBC: Apatinib + vinorelbine shows acceptable efficacy and safety in phase 2
MDedge Hematology and Oncology
HER2+ metastatic BC: Dual blockade with P + T effective and safe in routine clinical practice
MDedge Hematology and Oncology
Differential prognosis of germline BRCA1/2 mutations according to tumor subtypes
MDedge Hematology and Oncology
Re-BCS may not be the best strategy in ipsilateral breast tumor recurrence
MDedge Hematology and Oncology
pT1a-b ER+ BC: Endocrine therapy benefits patients with grade 2-3 tumors
MDedge Hematology and Oncology
Risk for second primary colorectal, pancreatic, and thyroid cancers elevated in male BC survivors
MDedge Hematology and Oncology
Contraceptive use during and after BC diagnosis in premenopausal women
MDedge Hematology and Oncology
Risk for persistent sedative-hypnotic use among patients receiving adjuvant chemotherapy
MDedge Hematology and Oncology
High IL-6 and CRP levels predict chemotherapy-induced clinical decline in older BC patients
MDedge Hematology and Oncology